argenx SE ADR (ARGX)
NASDAQ: ARGXHealthcareBiotechnologyUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
After hours: 928.44 0.00%
ARGX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $57.74B
- P/E (TTM)
- 35.38
- Forward P/E
- 26.74
- EPS (TTM)
- $26.24
- Dividend yield
- None
- 52-week range
- 661.85 – 1,072.75
- Day range
- 921.82 – 942.42
- Volume / Avg
- 244.87K / 283.20K
- Beta
- —
- Shares outstanding
- 62.19M
- Next earnings
- Oct 22, 2026
52-week range
ARGX stock today
Shares of argenx (ARGX) finished lower on Oct 7 at $928.44, a drop of 0.22% or $2.08 per share, versus the S&P 500's 0.22% decline. At this level, ARGX sits in the middle of its 52-week range of $661.85 to $1,072.75: 13.5% below the high, set on Sep 2, 2026 and 40.3% above the low. ARGX is up 10.5% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 16.5%.
At 35.4x trailing earnings, argenx trades in line with the peer-group median of 34.0x. Its forward P/E of 26.7x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year. The company is scheduled to report Sep/2026 results on Oct 22 before the market opens; analysts expect EPS of $7.48.
Summary generated from market data by MetaCap's automated system. Methodology
About argenx
Company profileargenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave's disease, myositis, Sjögren's disease, systemic sclerosis, and AMR; empasiprubart for MMN, delayed graft function, and CIDP; and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Ms. Karen Massey
- Headquarters
- Amsterdam
- Employees
- 1,863
- IPO year
- 2017
- Website
- argenx.com
Financial highlights
Full financialsNet income was $1.29 billion (+55.1% year over year). Diluted earnings per share came in at $19.57, up from $12.78.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | $35.53M | $10.03M | $497.28M |
| Growth | — | — | +254.41% | -97.98% | +1105.72% |
| Net income | $1.29B | $833.04M | $-295.05M | $-709.59M | $-408.26M |
| EPS (diluted) | $19.57 | $12.78 | $-5.16 | $-13.05 | $-7.99 |
Analyst forecast
ForecastConsensus (13 analysts)
buy
Avg. price target
$1,180.26+27.12%
- Strong buy 3
- Buy 8
- Hold 2
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Oct 22, 2026
- EPS estimate
- $7.48
ARGX news
All ARGX news- BMY or ARGX: Which Is the Better Value Stock Right Now?NasdaqBMY, ARGX
- 10 Wall Street Analysts Think Argenx Stock Is Headed to At Least $1,200 -- Is the Stock a Buy Now?NasdaqARGX, C, MS, WFC
- iShares Biotechnology ETF Experiences Big InflowNasdaqIBB, REGN, NTRA, ARGX
- Here's Exactly Why Wall Street Thinks Argenx Stock Could Soar 23% Over the Next 12 MonthsNasdaqARGX, WFC, UBS
argenx peers
Healthcare sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| RVMDRevolution Medicines Inc. | 200.87 | +0.50% | $43.05B | vs ARGX |
| ONCBeOne Medicines Ltd. ADR | 364.02 | +0.34% | $41.41B | vs ARGX |
| REGNRegeneron Pharmaceuticals Inc. | 742.12 | +0.46% | $76.40B | vs ARGX |
| MRNAModerna Inc. | 196.48 | +4.81% | $78.44B | vs ARGX |
| RPRXRoyalty Pharma plc Class A | 56.76 | +0.57% | $32.80B | vs ARGX |
| ALNYAlnylam Pharmaceuticals Inc. | 224.41 | +0.21% | $30.03B | vs ARGX |
| ROIVRoivant Sciences Ltd. | 34.75 | -2.20% | $25.10B | vs ARGX |
| BNTXBioNTech SE ADR | 95.25 | -0.50% | $23.93B | vs ARGX |
Indexes, lists and sector
Appears in lists
argenx stock FAQ
What is argenx's stock price today?
ARGX last traded at $928.44 as of Oct 7, 4:00 PM EDT, down 0.22% on the day. Prices are delayed at least 15 minutes.
When is argenx's next earnings date?
argenx is expected to report earnings on Thursday, October 22, 2026. Analysts expect EPS of $7.48.
What is ARGX's P/E ratio?
ARGX trades at a trailing P/E ratio of 35.38 and a forward P/E of 26.74, compared with a median of 34.0 for its closest peers.
Who is argenx's CEO?
Ms. Karen Massey is the chief executive officer of argenx SE ADR, which has about 1,863 employees.
What is the ARGX 52-week high?
The 52-week high for ARGX is $1,072.75 and the 52-week low is $661.85. The stock is currently 13.5% below its high.